Drugs / IBIO-600
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07487376 | May 2026 → May 2027 expected | obesity disorder | iBio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-05-12 | iBio, Inc. | Regulatory iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update ibioinc.com ↗ |
| 2026-04-08 | iBio, Inc. | Regulatory iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia ibioinc.com ↗
today announced IBIO-600 has received Clinical Trial Notification (CTN) acknowledgement from Australia’s Therapeutic Goods Administration (TGA) and ethics approval from a Human Research Ethics Committee (HREC), enabling the initiation of a first-in-human clinical trial of IBIO-600 in Australia. |
| 2025-04-07 | iBio, Inc. | Results iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline ibioinc.com ↗
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days |
All press releases naming this drug 4 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBIO-600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07487376 ↗ |
| Route | Subcutaneous | “IBIO-600 Subcutaneous injection” NCT07487376 ↗ |